Announcements Trials
Browse Landscape

Phase

Phase 2 36Phase 1 21Phase 3 20Phase 1/2 11Phase EARLY_PHASE1 2Phase 2/3 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 1Borderline Resectable Pancreatic Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 61Cyclophosphamide 57pembrolizumab 39fludarabine 38Radiotherapy 30Nivolumab 30Biopsy 27Metformin 23Fluorodeoxyglucose F18 22Bevacizumab 22Specimen Handling 21Temozolomide 18Cisplatin 18Radiosurgery 17Carboplatin 16Fluorouracil 15Paclitaxel 14Dexamethasone 14Radiation 13Gemcitabine 13Etoposide 13Rituximab 12Positron Emission Tomography Computed Tomography 12Letrozole 12Irinotecan 12gallium 68 PSMA-11 11durvalumab 11atezolizumab 11X-Rays 11Surgical Procedures, Operative 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Interventional × dehydroftorafur × Clear all
NCT02896907 2025-04-30

Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery

Thomas Jefferson University

Phase EARLY_PHASE1 Completed
8 enrolled 9 charts
Gastrointestinal

Pancreatic Neoplasms

NCT03970252 2024-08-09

Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

Jonsson Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
28 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡